A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
Neurology
; 61(9): 1282-4, 2003 Nov 11.
Article
em En
| MEDLINE
| ID: mdl-14610140
ABSTRACT
The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes
/
Interferon beta
/
Síndrome de Guillain-Barré
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Neurology
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Reino Unido